Enhancement of a delayed hypersensitivity reaction to a contact allergen, by the systemic administration of interleukin-2.
- 1 April 1991
- journal article
- Vol. 72 (4) , 584-7
Abstract
The immunopharmacological effects of interleukin-2 (IL-2) on the sensitization and effector phases of the delayed-type hypersensitivity (DTH) reaction were studied using contact sensitivity to the haptenizing agent dinitrochlorobenzene (DNCB). When administered at the time of priming to DNCB, IL-2 had no effect on the subsequent magnitude of the response. Interleukin-2 was, however, able to increase the magnitude of the response when given at the time of secondary challenge; the degree of change was directly related to the dose of IL-2. The proportions of T cells in the draining lymph node and spleen of IL-2-treated animals decreased by approximately one-third, but there was no alteration to the balance between CD4+ and CD8+ T cells. The results suggest that the increase in DTH observed was due to a pharmacological effect rather than to an increase in T-cell number.This publication has 23 references indexed in Scilit:
- The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2.The Journal of Experimental Medicine, 1989
- INTERLEUKIN-2 CAN PREVENT AND REVERSE ANTIGEN-INDUCED UNRESPONSIVENESS IN CLONED HUMAN LYMPHOCYTES-T1988
- Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies.The Journal of Experimental Medicine, 1987
- Recombinant interleukin-2 directly augments the cytotoxicity of human monocytesNature, 1987
- In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.The Journal of Immunology, 1985
- Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.The Journal of Immunology, 1985
- The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.The Journal of Immunology, 1985
- Induction of human T lymphocyte motility by interleukin 2.The Journal of Immunology, 1985
- INVIVO ADMINISTRATION OF PURIFIED JURKAT-DERIVED INTERLEUKIN-2 IN MICE1984
- INTERLEUKIN-2 REVERSES DEFICIENT CELL-MEDIATED IMMUNE-RESPONSES IN RHEUMATOID-ARTHRITIS1984